Novartis on Tuesday raised its full-year earnings outlook following cost cuts, a breast cancer drug trial success and progress in boosting output of a radiotherapy drug against prostate cancer.
Tag Archive for: cost cuts
The focus of investors and Wall Street analysts is squarely on Biogen and Eisai Co Ltd’s new drug lecanemab that slowed the progress of the disease by 27% in a trial last month.